Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CDXS

CDXS - Codexis Inc Stock Price, Fair Value and News

3.16USD-0.31 (-8.93%)Delayed as of 23 May 2024, 02:46 pm ET

Market Summary

CDXS
USD3.16-0.31
Delayedas of 23 May 2024, 02:46 pm
-8.93%

CDXS Stock Price

View Fullscreen

CDXS RSI Chart

CDXS Valuation

Market Cap

244.8M

Price/Earnings (Trailing)

-3.76

Price/Sales (Trailing)

3.3

EV/EBITDA

-3.59

Price/Free Cashflow

-4.52

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-87.65%

Return on Equity

-82.16%

Return on Assets

-43.55%

Free Cashflow Yield

-22.15%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

74.2M

Rev. Growth (Yr)

31.51%

Rev. Growth (Qtr)

-35.72%

CDXS Earnings

Earnings (TTM)

-65.1M

Earnings Growth (Yr)

49.13%

Earnings Growth (Qtr)

-59.97%

Breaking Down CDXS Revenue

52 Week Range

1.453.84
(Low)(High)

Last 7 days

-6.5%

Last 30 days

21.0%

Last 90 days

20.6%

Trailing 12 Months

24.9%

How does CDXS drawdown profile look like?

CDXS Financial Health

Current Ratio

3.71

Debt/Equity

0.35

Debt/Cashflow

-1.82

CDXS Investor Care

Shares Dilution (1Y)

5.68%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202474.2M000
2023116.2M99.1M74.0M70.1M
2022122.1M135.0M132.7M138.6M
202172.4M82.9M101.3M104.8M
202067.5M70.2M66.7M69.1M
201962.1M60.9M65.9M68.5M
201856.1M59.3M66.2M60.6M
201748.8M43.2M38.3M50.0M
201643.0M53.0M50.5M48.8M
201535.0M34.5M44.4M41.8M
201427.5M27.1M30.6M35.3M
201368.6M52.7M30.3M31.9M
2012124.0M120.8M113.9M88.3M
2011112.4M114.0M120.2M123.9M
2010091.0M99.0M107.1M
200900082.9M

Tracking the Latest Insider Buys and Sells of Codexis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 01, 2024
ryali sriram
acquired
-
-
52,350
chief financial officer
Jan 01, 2024
dilly stephen george
acquired
-
-
143,425
see remarks
Jan 01, 2024
fitzgerald margaret nell
acquired
-
-
52,350
see remarks
Jan 01, 2024
norrett kevin
acquired
-
-
52,350
chief operating officer
Nov 15, 2023
dorgan byron l
sold
-42,168
2.1084
-20,000
-
Sep 11, 2023
norrett kevin
bought
15,479
1.7199
9,000
chief operating officer
Sep 08, 2023
ryali sriram
bought
19,856
1.7044
11,650
chief financial officer
Sep 08, 2023
dilly stephen george
bought
100,952
1.7263
58,479
see remarks
Sep 08, 2023
fitzgerald margaret nell
bought
20,064
1.6955
11,834
see remarks
Jun 13, 2023
smith david v
acquired
-
-
34,602
-

1–10 of 50

Which funds bought or sold CDXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
JANE STREET GROUP, LLC
added
4.00
30,327
189,961
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-10,534
24,465
-%
May 16, 2024
COMERICA BANK
unchanged
-
427
3,392
-%
May 15, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-18.77
-7,939
104,606
-%
May 15, 2024
Royal Bank of Canada
added
24.7
206,000
688,000
-%
May 15, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
added
51.98
69,118
162,634
0.03%
May 15, 2024
PARADIGM CAPITAL MANAGEMENT INC/NY
unchanged
-
396,000
3,141,000
0.15%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
12.52
16,000
73,000
-%
May 15, 2024
Voya Investment Management LLC
reduced
-22.2
-9,600
77,865
-%
May 15, 2024
Aristides Capital LLC
sold off
-100
-188,795
-
-%

1–10 of 48

Are Funds Buying or Selling CDXS?

Are funds buying CDXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDXS
No. of Funds

Unveiling Codexis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nantahala capital management, llc
6.6%
4,592,903
SC 13G/A
Feb 13, 2024
vanguard group inc
5.91%
4,128,428
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 24, 2024
blackrock inc.
10.3%
7,196,414
SC 13G/A
Jan 08, 2024
baillie gifford & co
4.90%
3,419,093
SC 13G/A
Aug 08, 2023
blackrock inc.
10.4%
6,932,344
SC 13G/A
Feb 14, 2023
nantahala capital management, llc
6.8%
4,487,782
SC 13G/A
Feb 14, 2023
casdin capital, llc
0%
0
SC 13G/A
Feb 10, 2023
ark investment management llc
6.00%
3,941,985
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
3,642,208
SC 13G/A

Recent SEC filings of Codexis Inc

View All Filings
Date Filed Form Type Document
May 14, 2024
8-K
Current Report
May 14, 2024
424B5
Prospectus Filed
May 14, 2024
EFFECT
EFFECT
May 02, 2024
S-3
S-3
May 02, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
Apr 25, 2024
DEFA14A
DEFA14A
Apr 25, 2024
DEF 14A
DEF 14A
Mar 06, 2024
8-K
Current Report
Feb 28, 2024
8-K
Current Report

Peers (Alternatives to Codexis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Codexis Inc News

Latest updates
Yahoo Singapore News21 May 202411:18 am
Yahoo Canada Shine On19 May 202401:46 pm

Codexis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-35.7%17,073,00026,561,0009,277,00021,323,00012,982,00030,374,50034,470,00038,406,00035,340,00024,500,50036,769,00025,453,00018,032,00021,033,50018,385,00014,967,00014,670,00018,650,00021,906,00012,319,00015,583,000
Costs and Expenses10.2%28,961,00026,279,50041,337,00033,949,00036,647,00043,624,50045,106,00041,015,00043,726,00034,886,00035,439,00029,939,00027,187,00024,956,50024,449,00021,074,00022,497,00019,596,50021,647,00018,942,00020,822,000
Operating Expenses-------------------21,647,00018,942,00020,822,000
  S&GA Expenses5.5%12,860,00012,184,00012,302,00013,365,00015,399,00012,312,50013,499,00010,656,00015,705,00011,723,00013,407,00012,795,00011,398,0008,741,5008,797,0008,522,0008,989,0007,322,0007,869,0007,896,0008,415,000
  R&D Expenses0.1%11,246,00011,234,00013,662,00017,334,00016,655,00019,689,00021,821,00019,089,00019,500,00016,357,00015,165,00012,826,00011,571,00010,355,00012,010,00010,853,00010,967,0008,872,5008,711,0008,274,0008,016,000
EBITDA Margin20.6%-0.80-1.01-1.02-0.51-0.36-0.20-0.20-0.11-0.14-0.17-0.12-0.25---------
Interest Expenses818.8%147,00016,00018,0003,0007,00012,00010,0007,0005,0008,0003,000-3,00037,00011,000-4,00033,0007,000-13,00022,000
Income Taxes-71.4%10,00035,0009,0009,00016,000151,0008,000108,0009,00068,500110,0008,0002,0008,00019,000307,0005,0005,000-7,00016,0003,000
Earnings Before Taxes-60.6%-11,495,000-7,157,000-34,899,000-11,514,000-22,601,000-12,453,000-9,984,000-2,532,000-8,347,000-10,121,5002,354,000-4,257,000-9,066,000-3,912,000-6,075,000-6,037,000-7,647,000-630,000336,000-6,491,000-5,133,000
EBT Margin19.3%-0.88-1.09-1.10-0.57-0.41-0.24-0.23-0.14-0.17-0.20-0.15-0.28---------
Net Income-60.0%-11,505,000-7,192,000-34,908,000-11,523,000-22,617,000-12,604,000-9,992,000-2,640,000-8,356,000-10,190,0002,244,000-4,265,000-9,068,000-3,920,000-6,094,000-6,344,000-7,652,000-635,000343,000-6,507,000-5,136,000
Net Income Margin19.3%-0.88-1.09-1.10-0.57-0.41-0.24-0.23-0.14-0.17-0.20-0.15-0.28---------
Free Cashflow16.3%-8,919,000-10,657,000-16,980,000-17,668,000-11,751,0004,950,00018,424,000-4,122,000-16,275,000-4,820,000-4,196,000-10,089,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets9.5%150137154207218250235235235246228212212222138142149149146147101
  Current Assets15.5%10893.0010312013016314614514516217417217418410310611511411011064.00
    Cash Equivalents-8.4%60.0065.0075.0092.0010311410990.0094.0011711913014015172.0076.0087.0092.0092.0093.0047.00
  Inventory-9.1%2.003.002.002.002.002.002.002.002.001.001.001.001.001.001.001.001.000.000.001.001.00
  Net PPE-5.3%15.0015.0015.0023.0024.0023.0023.0024.0023.0021.0016.0011.0010.0010.007.007.007.006.006.005.005.00
  Goodwill0%2.002.002.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00
Liabilities40.7%70.0050.0063.0083.0092.0010681.0076.0077.0082.0058.0050.0048.0052.0047.0047.0050.0044.0044.0048.0050.00
  Current Liabilities-18.8%29.0036.0038.0036.0038.0049.0032.0030.0029.0033.0033.0024.0023.0025.0020.0019.0022.0015.0015.0017.0019.00
  Long Term Debt-28.00--------------------
Shareholder's Equity-8.5%79.0087.0092.0012412614515415915916416916316417091.0095.0099.0010610399.0051.00
  Retained Earnings-2.3%-509-497-490-455-443-421-408-398-396-387-377-379-375-366-362-356-350-342-341-342-335
  Additional Paid-In Capital0.7%588584582580570566563558555552547543539537453451449448444441387
Accumulated Depreciation1.5%40.0039.00-------------------
Shares Outstanding0.9%71.0070.0070.0070.0067.0066.0065.0065.0065.0065.0065.0064.00---------
Float----122---384---738---656---1,070-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations29.4%-7,789-11,037-16,302-16,087-9,2124,91719,734-2,181-11,186660-192-8,295-6,440-1,492-3,474-10,073-1,425-3,661-990-5,058-2,851
  Share Based Compensation46.6%3,1712,1632,2832,7162,8092,9314,5313,2313,8383,0463,0162,8442,6871,6361,9841,9392,1691,1601,7321,9882,063
Cashflow From Investing-2687.2%-28,5631,104-1,107-1,571-3,28433.00-1,309-2,220-10,082-5,480-10,997-2,412-2,533-2,488-770-1,729-761-414-1,994-812-445
Cashflow From Financing-29,281--1086,9231,352339133233-1,2802,42686845617.0081,586125116-1,0192,4221,68851,933-2,082
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CDXS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 17,073$ 12,982
Costs and operating expenses:  
Cost of product revenue4,8554,521
Research and development11,24616,655
Selling, general and administrative12,86015,399
Restructuring charges072
Total costs and operating expenses28,96136,647
Loss from operations(11,888)(23,665)
Interest income9091,089
Other expense, net(516)(25)
Loss before income taxes(11,495)(22,601)
Provision for income taxes1016
Net loss$ (11,505)$ (22,617)
Net loss per share, basic (in dollars per share)$ (0.16)$ (0.34)
Net loss per share, diluted (in dollars per share)$ (0.16)$ (0.34)
Weighted average common stock shares used in computing net loss per share, basic (in shares)69,85465,931
Weighted average common stock shares used in computing net loss per share, diluted (in shares)69,85465,931
Product revenue  
Revenues:  
Total revenues$ 9,551$ 8,364
Research and development revenue  
Revenues:  
Total revenues$ 7,522$ 4,618

CDXS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 58,046$ 65,116
Restricted cash, current518519
Short-term investments27,4690
Financial assets:  
Accounts receivable6,24010,036
Contract assets2,571815
Unbilled receivables5,4599,142
Total financial assets14,27019,993
Less: allowances(65)(65)
Total financial assets, net14,20519,928
Inventories2,4412,685
Prepaid expenses and other current assets5,2695,218
Total current assets107,94893,466
Restricted cash1,0621,062
Investment in non-marketable equity securities9,7009,700
Right-of-use assets - Operating leases, net12,36413,137
Property and equipment, net14,66815,487
Goodwill2,4632,463
Other non-current assets1,3541,246
Total assets149,559136,561
Current liabilities:  
Accounts payable3,4655,947
Accrued compensation6,50211,246
Other accrued liabilities5,3744,735
Current portion of lease obligations - Operating leases3,8793,781
Deferred revenue9,86010,121
Total current liabilities29,08035,830
Deferred revenue, net of current portion630640
Long-term lease obligations - Operating leases11,23212,243
Long-term debt28,1020
Other long-term liabilities1,2481,233
Total liabilities70,29249,946
Commitments and Contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding00
Common stock, $0.0001 par value per share; 200,000 shares authorized; 70,554 shares and 69,905 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively77
Additional paid-in capital588,311584,138
Accumulated other comprehensive loss(16)0
Accumulated deficit(509,035)(497,530)
Total stockholders' equity79,26786,615
Total liabilities and stockholders' equity$ 149,559$ 136,561
CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
 CEO
 WEBSITEcodexis.com
 INDUSTRYBiotechnology
 EMPLOYEES248

Codexis Inc Frequently Asked Questions


What is the ticker symbol for Codexis Inc? What does CDXS stand for in stocks?

CDXS is the stock ticker symbol of Codexis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codexis Inc (CDXS)?

As of Wed May 22 2024, market cap of Codexis Inc is 244.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers. The fair value of Codexis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Codexis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Codexis Inc a good stock to buy?

The fair value guage provides a quick view whether CDXS is over valued or under valued. Whether Codexis Inc is cheap or expensive depends on the assumptions which impact Codexis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXS.

What is Codexis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, CDXS's PE ratio (Price to Earnings) is -3.76 and Price to Sales (PS) ratio is 3.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Codexis Inc's stock?

In the past 10 years, Codexis Inc has provided 0.1 (multiply by 100 for percentage) rate of return.